Annals of Pediatric Endocrinology & Metabolism

Principles of Transparency
and Best Practice

Page Path

HOME
ABOUT
Principles of Transparency and Best Practice

Principles of Transparency and Best Practice in APEM

1. Website
2. Name of Journal
3. Peer Review Process
4. Ownership and Management
- i) Information about the ownership
- ii) Management team of a journal
5. Governing Body
6. Editorial Team and Contact Information
- i) Editorial team
- ii) Contact information
7. Copyright and Licensing
8. Author Fees
9. Process for Identification of and Dealing With Allegations of Research Misconduct
10. Publication Ethics
11. Publishing Schedule
12. Access
13. Archiving
14. Revenue Sources
15. Advertising
16. Direct Marketing

1. Website

i) The URL address of official journal web site

https://e-apem.org/

ii) ‘Aims & Scope’ statement (https://e-apem.org/about/index.php)

The aims of Annals of Pediatric Endocrinology & Metabolism are to contribute to the advancements in the fields of pediatric endocrinology & metabolism through the scientific reviews and interchange of all of pediatric endocrinology and metabolism. It aims to reflect the latest clinical, translational, and basic research trends from worldwide valuable achievements. In addition, genome research, epidemiology, public education and clinical practice guidelines in each country are welcomed for publication. The Journal particularly focuses on research conducted with Asian-Pacific children whose genetic and environmental backgrounds are different from those of the Western.
Area of specific interest include the following :
Growth, puberty, glucose metabolism including diabetes mellitus, obesity, nutrition, disorders of sexual development, pituitary, thyroid, parathyroid, adrenal cortex, bone or other endocrine and metabolic disorders from infancy through adolescence

iii) Readership

• It is primarily for pediatricians who seek tailored information they are able to adopt in their research and practice, but its readership can be expanded to other positions;
• Researchers have access to recent clinical pediatric endocrinology and metabolism research topics and detailed research methods;
• Clinicians in the field have access to new information and recent pediatric care developments for their patients;
• Medical teachers are able to access and adopt a variety of medical education data;
• Allied health professionals, including nurses, have access to recent information concerning the care of children with endocrine and metabolic diseases;
• Medical health students can learn about recent trends in the field and read about interesting cases;
• Policymakers are able to reflect on the article results and apply them in nationwide healthcare policies for children with endocrine and metabolic diseases;
• The public, especially families with children who have endocrine and metabolic diseases, are able to read about the advancements in their children’s diseases, increasing their knowledge and inspiring confidence in the pediatricians’ devotion to their children.

iv) Authorship criteria

Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval of the version to be published; and 4) agreeing to be accountable for all aspects of the work in ensuring that the questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Authors should meet these 4 conditions. If the number of authors is greater than 6, there should be a list of each author's role in the submitted paper. If any persons who do not meet the above four criteria, they may be placed as contributors in the Acknowledgments section. Description of co-first authors or co-corresponding authors is also accepted if the corresponding author believes that such roles existed in contributing to the manuscript.

v) Duplicate submission and redundant publication

All submitted manuscripts should be original and should not be in consideration by other scientific journals for publication. Any part of the accepted manuscript should not be duplicated in any other scientific journal without the permission of the Editorial Board, although the figures and tables can be used freely if the original source is verified according to Creative Commons license. It is mandatory for all authors to resolve any copyright issues when citing a figure or table from other journal that is not open access.

vi) ISSN

pISSN 1226-2242, eISSN 2287-1292

2. Name of Journal

The Annals of Pediatric Endocrinology & Metabolism Journal is the official publication of the Korean Society of Pediatric Endocrinology. Its formal abbreviated title is “Ann Pediatr Endocrinol Metab”. It is a peer-reviewed open access journal of medicine published in English. The journal was launched in 1996 under the title of ‘Journal of Korean Society of Pediatric Endocrinology’ until 2011 (pISSN 1226-2242). Since 2012, the title is now changed to ‘Annals of Pediatric Endocrinology & Metabolism’.

3. Peer Review Process

APEM reviews all received materials. Manuscripts are sent to the two most relevant investigators available for review of the contents. The editor selects peer referees by recommendation of APEM’s editorial Board members or from the Board`s specialist database. General scheme is presented in Fig. 1.

Accepted: The manuscript will be forwarded to the publisher without further corrections.
Minor revisions: The author should address the comments from the reviewers, which will be confirmed by the reviewers before being sent to the publisher.
Major revisions: The author should address the comments from the reviewers and make the appropriate corrections for review by the three reviewers.
Rejection: When one out of the two reviewers rejects the manuscript, the final decision is made by the editorial committee.
Consultation: Review of the manuscript will be done through consultation to subcommittees and subspecialties.

4. Ownership and Management

i) Information about the ownership: This journal is owned by the publisher, Korean Society of Pediatric Endocrinology
(http://www.kspendo.or.kr)
ii) Management team: Journal Manager
Jung Sub Lim Editor-in-Chief, Korean Cancer Center Hospital, Seoul, Korea; Manager of the Review Process
Ji-Young Seo Associate Editor, Eulji University, Seoul, Korea; Manuscript Editor
Hwan Tae Ahn Korean Spinal Neurosurgery Society, Korea; Website and JATS XML File Producers
Yoon-Sang Cho M2community, Korea

5. Governing Body

The governing body is the journal's editorial board (https://e-apem.org/about/editorial.php).

6. Editorial Team and Contact Information

i) Editorial team: Editorial Board’s website is https://e-apem.org/about/editorial.php.
All of the members are responsible to improve the scientific quality of the journal and to implement editorial policy approved by the editorial board.
ii) Contact information: Publisher Korean Society of Pediatric Endocrinology
#510, DoosanBearstel 381, Gangnam-daero, Seocho-gu, Seoul 06620, Korea
Tel: +82-2-3471-4268 Fax: +82-2-3471-4269
E-mail: kspe.editor@gmail.com
Editorial Office
#510, DoosanBearstel 381, Gangnam-daero, Seocho-gu, Seoul 06620, Korea
Tel: +82-2-3471-4268 Fax: +82-2-3471-4269
E-mail: apem@gmail.com

7. Copyright and Licensing

i) Copyright policy: All published papers become the permanent property of Korean Society of Pediatric Endocrinology. Copyrights of all published materials are owned by Korean Society of Pediatric Endocrinology. Permission must be obtained from Korean Society of Pediatric Endocrinology for any commercial use of materials. Every author should sign the copyright transfer agreement forms.
ii) Licensing information: This is an open-access journal distributed under the terms of the Creative Commons Attribution Non-commercial license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited for non-commercial purpose (http://creativecommons.org/licenses/by-nc/4.0/").
iii) Deposit policy: Full text of APEM has been archived in PubMed Central (PMC)
(https://www.ncbi.nlm.nih.gov/pmc/journals/2434/) from the 18th volume, 2013.
According to the deposit policy (self-archiving policy) of Sherpa/Romeo (http://www.sherpa.ac.uk/), authors cannot archive pre-print (i.e. pre-refereeing), but they can archive post-print (i.e. final draft post-refereeing). Authors can archive publisher's version/PDF. APEM provides the electronic backup and preservation of access to the journal content in the event the journal is no longer published by archiving in PubMed Central. Authors can archive publisher's version/PDF.

8. Author Fees

There is no article processing charge (APC). A minimum of 100 off prints will be delivered after payment. Reprints are available at any time after publication; however, reprints ordered after publication may be subject to increases in price. The corresponding author will be requested to pay a page charge and color photographs require an additional fee.

9. Process for Identification of and Dealing With Allegations of Research Misconduct

When the Journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, an ethical problem discovered with the submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and other issues, the resolving process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). The Editorial Board will discuss the suspected cases and reach a decision. We will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when needed.
APEM adheres to the research and publication ethics policies outlined in International Standards for Editors and Authors (http://publicationethics.org) and the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://icmje.org). Any studies involving human subject must comply with the principles of the World Medical Association Declaration of Helsinki. Clinical research should be approved by the Institutional Review Board, as well through patient consent. A patient's personal information cannot be published in any form. However, if it is absolutely necessary to use a patient's personal information, the consent of the patient or his/her guardian will be needed before publishing. Animal studies should be performed in compliance with all relevant guidelines, observing the standards described in the NIH Guide for the Care and Use of Laboratory Animals.
Cases that require editorial expressions of concern or retraction shall follow the COPE flowcharts available from: http://publicationethics.org/resources/flowcharts. If correction is needed, it will follow the ICMJE Recommendation for Corrections, Retractions, Republications and Version Control available from:
http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/corrections-and-version-control.html as follows:
Honest errors are a part of science and publishing and require publication of a correction when they are detected. Corrections are needed for errors of fact. Minimum standards are as follows: First, it shall publish a correction notice as soon as possible, detailing changes from and citing the original publication on both an electronic and numbered print page that is included in an electronic or a print Table of Contents to ensure proper indexing; Second, it shall post a new article version with details of the changes from the original version and the date(s) on which the changes were made through CrossMark; Third, it shall archive all prior versions of the article. This archive can be either directly accessible to readers; and Fourth, previous electronic versions shall prominently note that there are more recent versions of the article via CrossMark.

10. Publication Ethics

i) Journal policies on authorship and contributorship

Authorship
Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval of the version to be published; and 4) agreeing to be accountable for all aspects of the work in ensuring that the questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Authors should meet these 4 conditions. If the number of authors is greater than 6, there should be a list of each author's role in the submitted paper. If any persons who do not meet the above four criteria, they may be placed as contributors in the Acknowledgments section. Description of co-first authors or co-corresponding authors is also accepted if the corresponding author believes that such roles existed in contributing to the manuscript.

Originality and duplicate publication
All submitted manuscripts should be original and should not be in consideration by other scientific journals for publication. Any part of the accepted manuscript should not be duplicated in any other scientific journal without the permission of the Editorial Board, although the figures and tables can be used freely if the original source is verified according to Creative Commons license. It is mandatory for all authors to resolve any copyright issues when citing a figure or table from other journal that is not open access.

Secondary publication
It is possible to republish manuscripts if the manuscripts satisfy the condition of secondary publication of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals by International Committee of Medical Journal Editors (ICMJE), available from http://www.icmje.org/. These are:

• The authors have received approval from the editors of both journals (the editor concerned with the secondary publication must have access to the primary version).
• The priority for the primary publication is respected by a publication interval negotiated by editors of both journals and the authors.
• The paper for secondary publication is intended for a different group of readers; an abbreviated version could be sufficient.
• The secondary version informs readers, peers, and documenting agencies that the paper has been published in whole or in part elsewhere—for example, with a note that might read, "This article is based on a study first reported in the [journal title, with full reference]"—and the secondary version cites the primary reference.
• The title of the secondary publication should indicate that it is a secondary publication (complete or abridged republication or translation) of a primary publication. Of note, the United States National Library of Medicine (NLM) does not consider translations to be "republications" and does not cite or index them when the original article was published in a journal that is indexed in MEDLINE.

ii) How the journal will handle complaints and appeals

iii) Journal policies on conflicts of interest/competing interests

Conflict of interest exists when an author or the author’s institution, reviewer, or editor has financial or personal relationships that inappropriately influence or bias his or her actions. Such relationships are also known as dual commitments, competing interests, or competing loyalties. These relationships vary from being negligible to having great a potential for influencing judgment. Not all relationships represent true conflict of interest. On the other hand, the potential for conflict of interest can exist regardless of whether an individual believes that the relationship affects his or her scientific judgment. Financial relationships such as employment, consultancies, stock ownership, honoraria, and paid expert testimony are the most easily identifiable conflicts of interest and the most likely to undermine the credibility of the journal, the authors, or of the science itself. Conflicts can occur for other reasons as well, such as personal relationships, academic competition, and intellectual passion (http://www.icmje.org/conflicts-of-interest/). If there are any conflicts of interest, authors should disclose them in the manuscript. The conflicts of interest may occur during the research process as well; however, it is important to provide disclosure. If there is a disclosure, editors, reviewers, and reader can approach the manuscript after understanding the situation and background for the completed research.

iv) Journal policies on data sharing and reproducibility

Until 2020, authors will be encouraged to share their data openly, but they will be mandated to do so. The related regulation follows the open data sharing policy outlined below.

Open data sharing policy
For clarification on result accuracy and reproducibility of the results, raw data or analysis data will be deposited to a public repository, for example, Harvard Dataverse (https://dataverse.harvard.edu/dataverse/apem/) after acceptance of the manuscript. Therefore, submission of the raw data or analysis data is optional at present but starting in 2023, they will be mandated. If the data is already a public one, its URL site or sources should be disclosed. If data cannot be publicized, it can be negotiated with the editor. If there are any inquiries on depositing data, authors should contact the editorial office.

Clinical data sharing policy
This journal follows the data sharing policy described in “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors” (https://doi.org/10.3346/jkms.2017.32.7.1051). As of July 1, 2018 manuscripts submitted to ICMJE journals that report the results of interventional clinical trials must contain a data sharing statement as described below. Clinical trials that begin enrolling participants on or after January 1, 2019 must include a data sharing plan in the trial's registration. The ICMJE's policy regarding trial registration is explained at https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. If the data sharing plan changes after registration this should be reflected in the statement submitted and published with the manuscript, and updated in the registry record. All of the authors of research articles that deal with interventional clinical trials must submit data sharing plan of example 1 to 4 in Table 1. Based on the degree of sharing plan, authors should deposit their data after deidentification and report the DOI of the data and the registered site.
Table 1. Examples of data sharing statements that fulfill these ICMJE requirements*

Element	Example 1	Example 2	Example 3	Example 4
Will individual participant data be available (including data dictionaries)?	Yes	Yes	Yes	Yes
What data in particular will be shared?	All individual participant data collected during the trial, after deidentification.	Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).	Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).	Not available
What other documents will be available?	Study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code	Study protocol, statistical analysis plan, analytic code	Study protocol	Not available
When will data be available (start and end dates)?	Immediately following publication. No end date.	Beginning at 3 months and ending at 5 years following the article publication.	Beginning at 9 months and ending at 36 months following the article publication.	Not applicable
With whom?	Anyone who wishes to access the data.	Researchers who provide a methodologically sound proposal.	Investigators whose proposed use of the data has been approved by an independent review committee (“learned intermediary”) identified for this purpose.	Not applicable
For what types of analyses?	Any purpose	To achieve aims in the approved proposal.	For individual participant data meta-analysis.	Not applicable
By what mechanism will data be made available?	Data are available indefinitely at (link to be included).	Proposals should be directed to xxx@yyy. To gain access, data requestors will need to sign a data access agreement.	Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata.	Not applicable
		Data are available for 5 years at a third-party website (link to be included).	Information regarding submitting proposals and accessing data may be found at (link to be provided).

ICMJE, International Committee of Medical Journal Editors.
*These examples are meant to illustrate a range of, but not all, data sharing options.

v) Journal's policy on ethical oversight

vi) Journal's policy on intellectual property

All published papers become the permanent property of the Korean Society of Pediatric Endocrinology. Copyrights of all published materials are owned by the Korean Society of Pediatric Endocrinology.

vii) Journal's options for postpublication discussions and corrections

The postpublication discussion is available through letter to the editor. If any readers have a concern on any articles published, they can submit letter to the editor on the articles. If there founds any errors or mistakes in the article, it can be corrected through errata, corrigenda, or retraction.

11. Publishing Schedule

It is published in English quarterly on the last days of March, June, September, and December.

12. Access

This is an open-access journal distributed under the term of the Creative Common Attribution Non-Commercial License (http://creative-commons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

13. Archiving

It is accessible without barrier from PubMed Central (https://www.ncbi.nlm.nih.gov/pmc/journals/3453/) Korea Citation Index (https://kci.go.kr), or National Library of Korea (http://nl.go.kr) in the event a journal is no longer published.

14. Revenue Sources

Revenue sources of journal were from the support of publisher (the Korean Society of Pediatric Endocrinology), Korea Government’s support, author fee for print copies, and advertising rates.

15. Advertising

Annals of Pediatric Endocrinology & Metabolism does not accept any commercial product advertisements until policy changes otherwise.

16. Direct Marketing

Journal propagation has been done through the journal web site and distribution of an eTOC. Invitations to submit a manuscript are usually focused on the presenters at conferences, seminars, or workshops if the topic is related to the journal's aims and scope.